Early clinical diagnosis of an under-recognized form of amyloidosis that causes rapidly progressing polyneuropathy is crucial to improving patient outcomes. Worldwide, the most common mutation ...

Vutrisiran is already approved as Amvuttra to treat rare disease hereditary ATTR amyloidosis ... before the end of this year in the genetic eye disease, which causes fatty material to build ...